Universidade Federal de Mato Grosso, Institute for Collective Health - Cuiabá (MT), Brazil.
Universidade do Estado de Mato Grosso - Tangará da Serra (MT), Brazil.
Rev Bras Epidemiol. 2023 May 8;26:e230026. doi: 10.1590/1980-549720230026. eCollection 2023.
To analyze the use of ivermectin as COVID-19 prevention method by the population of Mato Grosso in 2020.
This is a home-based survey, carried out between September and October 2020, in 10 pole cities of the socioeconomic regions of State. The use of ivermectin was evaluated through the question: "Did you take ivermectin to prevent COVID-19?". Sociodemographic variables (sex, age group, education, family income), current work situation, being benefitted by government financial programs, as well as symptoms, seroprevalence of antibodies against SARS-CoV-2, and previous diagnosis of COVID-19 were evaluated. Prevalence and their associations were estimated using the chi-square test.
4.206 individuals were evaluated for prevalence of ivermectin use; 58.3% of the individuals responded positively, this rate being higher in the municipalities of the western region of the state (66.6%). There was no significant difference between sexes, but the prevalence was higher among people aged 50-59 years (69.7%), who were white (66.5%), with complete higher education or more (68.8%) and higher family income (≥3 minimum wages-64.2%). The use of this drug was even higher among participants who considered their knowledge of the disease good or very good (65.0%), who reported having symptoms of COVID-19 (75.3%), and who had been previously diagnosed with the disease (91.2%).
There was a high prevalence of use of ivermectin as a method to prevent covid-19 by the population of Mato Grosso, indicating the need for strategies to inform the population about the risks of off-label use of drugs and to combat the advertising of drugs that are ineffective against COVID-19.
分析 2020 年马托格罗索州居民将伊维菌素用作 COVID-19 预防方法的情况。
这是一项基于家庭的调查,于 2020 年 9 月至 10 月在该州社会经济区域的 10 个首府城市进行。通过以下问题评估伊维菌素的使用情况:“您是否服用伊维菌素预防 COVID-19?”。评估了社会人口学变量(性别、年龄组、教育程度、家庭收入)、当前工作状况、是否受益于政府财政计划,以及症状、针对 SARS-CoV-2 的抗体血清阳性率和之前的 COVID-19 诊断情况。使用卡方检验估计了患病率及其关联。
对 4206 名个体进行了伊维菌素使用的患病率评估;58.3%的个体回答为阳性,该州西部地区的市镇这一比例更高(66.6%)。性别之间无显著差异,但 50-59 岁人群的患病率更高(69.7%),他们是白人(66.5%),具有完整的高等教育或以上(68.8%)和更高的家庭收入(≥3 最低工资-64.2%)。认为自己对疾病的了解良好或非常好的参与者(65.0%)、报告有 COVID-19 症状的参与者(75.3%)和以前被诊断出患有该疾病的参与者(91.2%)使用这种药物的比例更高。
马托格罗索州居民将伊维菌素作为预防 COVID-19 的方法的使用率很高,这表明有必要制定策略,向公众宣传药物标签外使用的风险,并打击宣传对 COVID-19 无效的药物。